November 25, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
CD22 Redirected Autologous T Cells for ALL
Issue: November/December 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-zeta and 4-1BB (TCR-zeta/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
